Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice (Q73515406)
Jump to navigation
Jump to search
scientific article published on 01 March 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice |
scientific article published on 01 March 2000 |
Statements
Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice (English)
U Schumacher
S Feldhaus